Max
HealthPrize Technologies
Vishal Khanna, Vice President of Marketing & Communications
vkhanna@healthprize.com
In September 2019, HealthPrize Technologies introduced its newest product, Max. Built using HealthPrize’s market-proven technology platform, Max is a single, integrated medication adherence experience targeting the most common chronic conditions. HealthPrize recruits Rx-verified patients to engage daily with Max, across their entire medication cabinet, to build positive medication-taking habits, track their prescriptions, and take control of their own health.
Max overcomes several challenges that have typically been barriers to success for pharma-based adherence programs, including MLR review timing, complications, and program scalability.
Pharmaceutical clients can set patient recruitment targets at any level of scale. Enrollment is limited to patients verified to be on the specified therapy who receive invitations from Max’s evolving partner ecosystem of pharmacies and population health companies.
Because Max is not client-branded, medication-specific, nor customizable, it requires limited effort from client brand teams, while providing the same high levels of engagement and adherence lift as branded adherence programs. Rx-verified patients engage daily with health content and actionable behavioral triggers specific to all of their reported medications, and refill activities are verified directly from Max’s partners to demonstrate adherence lift.
Max uses gamification tactics such as streaks, structured sweepstakes, and atomized content to ensure high levels of engagement and education. Behavioral economics concepts are used to turn the negative experience of medicine taking into a positive one. The product delivers targeted, personalized messaging to patients and rewards product use to support brand loyalty.
Max covers the most common primary care chronic conditions, including: Acne, Atopic Dermatitis, COPD, Diabetes, Hyperlipidemia, Hypertension, Kidney Disease, and Rheumatoid Arthritis. HealthPrize is now in discussions with pharmaceutical brands regarding initiatives targeting start dates in the Spring of 2020.
